Drug reference
Benralizumab
Monoclonal Antibody · Anti-asthmatic
Monoclonal AntibodyAnti-asthmatic
CDSCO approvedSchedule H
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Benralizumab is a humanized IgG1 monoclonal antibody. It targets the interleukin-5 (IL-5) receptor, contributing to anti-inflammatory therapy for asthma by affecting specific inflammatory pathways.
Indications
Severe eosinophilic asthma (in adults)maintenance treatment of severe asthma (eosinophilic phenotype)
Side effects
Common
Minimal side effects reported.
Related guidelines
Other Monoclonal Antibody drugs
Ask House about Benralizumab
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e, Katzung, BNF·Verified: 2026-05-10 · House clinical team